The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Antitumor immunity as the basis for durable disease-free, treatment-free survival (DDFTFS) in patients with metastatic urothelial cancer (mUC).
 
Jonathan Forrest Anker
Patents, Royalties, Other Intellectual Property - Co-inventor on patent "IMMUNOSTIMULATORY BACTERIA FOR THE TREATMENT OF CANCER", Publication number 20190046588 (Inst)
 
Sumanta Monty Pal
Research Funding - Allogene Therapeutics (Inst); crispr therapeutics (Inst); Eisai (Inst); Exelixis (Inst); Genentech (Inst); Pfizer (Inst); Roche (Inst)
Travel, Accommodations, Expenses - crispr therapeutics; Roche
 
Seunghee Kim-Schulze
No Relationships to Disclose
 
Huan Wang
Employment - Sema4; Sema4
Stock and Other Ownership Interests - Sema4
 
Rebecca Halperin
Employment - Sema4
Stock and Other Ownership Interests - Sema4
 
Andrew Uzilov
Employment - Sema4; Sema4 (I)
Stock and Other Ownership Interests - Sema4; Sema4 (I)
 
Takuro Saito
Research Funding - Takeda Science Foundation
 
Noah M. Hahn
Honoraria - Bladder Cancer Academy; PeerView; PlatformQ Health
Consulting or Advisory Role - AstraZeneca; Boehringer Ingelheim; Celgene; Champions Oncology; CicloMed; Ferring; Genentech/Roche; GlaxoSmithKline; Health Advances; ImmunityBio; Incyte; Janssen; Merck; Mirati Therapeutics; Pfizer; Pfizer/EMD Serono; Principa Biopharma; Seattle Genetics/Astellas; Taris BioMedical; Trans Med
Research Funding - Acerta Pharma (Inst); Astex Pharmaceuticals (Inst); AstraZeneca/MedImmune (Inst); Bristol-Myers Squibb (Inst); Genentech/Roche (Inst); HTG Molecular Diagnostics (Inst); Incyte (Inst); Merck (Inst); Merck (Inst); Merck (Inst); Pieris Pharmaceuticals (Inst); Principa Biopharma (Inst); Seattle Genetics/Astellas (Inst)
 
Manishkumar Patel
No Relationships to Disclose
 
Jingjing Qi
No Relationships to Disclose
 
Hui Xie
No Relationships to Disclose
 
Nina Bhardwaj
Leadership - American Association for Cancer Research
Stock and Other Ownership Interests - Apricity Health; Genotwin; PrimeVax
Honoraria - Pfizer; U.S. Food and Drug Administration
Consulting or Advisory Role - American Association for Cancer Research; Apricity Health; BioNTech SE; Boehringer Ingelheim; BreakBio Corp.; Carisma Therapeutics; CureVac; Genotwin; Gilead Sciences; Novartis; Parker Institute for Cancer Immunotherapy; PrimeVax; Roche/Genentech; rome; Rubius Therapeutics; Tempest Therapeutics
Research Funding - Celldex (Inst); Genentech (Inst); Novocure (Inst); Oncovir (Inst); Regeneron (Inst)
Travel, Accommodations, Expenses - Parker Institute for Cancer Immunotherapy
 
Sacha Gnjatic
Research Funding - Boehringer Ingelheim (Inst); Bristol-Myers Squibb/Medarex (Inst); Celgene (Inst); EMD Serono (Inst); Janssen (Inst); Regeneron (Inst); Takeda (Inst)
Patents, Royalties, Other Intellectual Property - Patent on GM-CSF autoantibodies; Patent on Multiplex Immunohistochemistry with Chromogen Staining on a Single Slide (MICSSS); Patents related to immune composition of NY-ESO-1 and peptides; Provisional patent on ELLA cytokines
 
Matt D. Galsky
Stock and Other Ownership Interests - Rappta Therapeutics
Consulting or Advisory Role - Aileron Therapeutics; Astellas Pharma; AstraZeneca; Basilea; BioMotiv; Bristol-Myers Squibb; Dendreon; Dracen; Dragonfly Therapeutics; EMD Serono; Genentech; Gilead Sciences; GlaxoSmithKline; Incyte; Infinity Pharmaceuticals; Inovio Pharmaceuticals; Janssen; Lilly; Merck; Novartis; NuMab; Pfizer; Seagen; Silverback Therapeutics; Urogen pharma
Research Funding - AstraZeneca (Inst); Bristol-Myers Squibb (Inst); Dendreon (Inst); Genentech/Roche (Inst); Janssen Oncology (Inst); Merck (Inst); Novartis (Inst)
Patents, Royalties, Other Intellectual Property - METHODS AND COMPOSITIONS FOR TREATING CANCER AND RELATED METHODS. MOUNT SINAI SCHOOL OF MEDICINE July 2012 Application number: 20120322792